Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Psoriatic arthritis (PsA) diagnosed \> 6months prior~* Active PsA at the time of screening and at baseline visits, with \>= 3 swollen joints and \>= 3 tender joints~* Have at least 1 of the PsA subsets (DIP joint arthritis, polyarticular arthritis without rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis)~* Active plaque psoriasis with a lesion \>= 2cm in diameter~* Active arthritis despite current disease modifying anti-rheumatic drug (DMARD) or nonsteroidal anti-inflammatory drug (NSAID) therapy~* Stable doses of methotrexate, low-dose corticosteroids, and NSAIDs are permitted.~Exclusion Criteria:~* No prior treatment with biologic anti-TNF agents (infliximab, etanercept, adalimumab)~* No treatment with alefacept or efalizumab within 3 months prior to the first study drug injection~* No DMARDs other than methotrexate, or immunosuppressive drugs within 4 weeks prior to the first study drug injection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 002 (Type: EXPERIMENTAL): golimumab 50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
- 001 (Type: EXPERIMENTAL): Placebo; golimumab SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
- 003 (Type: EXPERIMENTAL): golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs

Based on this trial design, predict the completion outcome and termination type (if applicable).